Feature | July 29, 2013

GE Healthcare Recalls Many of its Nuclear Imaging Systems

Patient's death from falling scanner component spurs total safety recall

July 29, 2013 — GE Healthcare has initiated a Class I recall of most of its SPECT nuclear imaging systems and called for its systems to not be operated until the vendor can inspect the scanner. The recall follows the death of a patient after a portion of the scanner fell onto them during the scan on an Infinia Hawkeye 4 system at a VA medical center facility in New York.

On June 17, GE sent an urgent medical device correction letter to all affected customers. The letter identified the affected product, and recommended that qualified service personnel maintain the equipment and that preventative maintenance procedures are executed according to labeling. In addition, users were told that safety chapter sections should be re-reviewed with personnel to ensure proper operation of the equipment.

On July 3, GE notified hospitals again via an urgent medical device recall letter and follow-up telephone calls, notifying that it was recalling several more of its nuclear imaging systems. The company said serious injuries or death could occur due to the failure mode associated with the recall. In the second notification, GE included most of its nuclear medicine systems, including the Infinia nuclear medicine systems, VG and VG Hawkeye nuclear medicine systems, Helix nuclear medicine systems, Brivo NM615, Discovery NM630, Optima NM/CT640 and the Discovery NM/CT670.

Healthcare facilities are instructed to cease use of the above mentioned nuclear imaging systems until a GE Healthcare field engineer is able to do a complete inspection of the system and perform any necessary repairs at no cost. GE Healthcare representatives will contact hospitals to arrange for the inspection. If an issue with the support mechanism fasteners is found on a system, the GE field engineer will coordinate the replacement of impacted parts in the gantry to ensure the system is operating safely and meets all specifications.

The weight of nuclear imaging cameras is around 1,300 pounds due to the cameras being lead lined and additional lead in the construction of the internal collimation system.  This significant weight poses design challenges in these systems because of the fatigue on the supports. This is an issue faced by all vendors' system and is not unique to GE. 
 

Investigation of the Accident

In its July 3 recall letter, GE said it was informed of the patient’s death on June 5. GE Healthcare responded and is working with the facility and all appropriate government agencies to complete a thorough investigation.

The company was permitted access to the equipment on June 17. GE Healthcare determined the bolts securing the camera to the gantry were loose, thereby stressing the support mechanism and resulting in the incident. The safety concern is related to a potential patient entrapment or crush hazard if the camera falls during a patient exam, the company said.

Because of the similarities in the design of support mechanisms across many GE products, the company included in its June 17 recall all types and manufacturing dates of Infinia and Infinia Hawkeye nuclear medicine systems; all types and manufacturing dates of VG and VG Hawkeye nuclear medicine systems; and all types and manufacturing dates of Helix nuclear medicine systems by Elscint Ltd. In the July 3 letter the company expanded this recall to include the Brivo NM615, Discovery NM630, Optima NM/CT640 and the Discovery NM/CT670 due to similarities in basic mechanical concepts between these devices and the Infinia systems.

As of Aug. 1, GE reported it had nearly complete its inspections of its SPECT systems installed globally and that systems requiring repair will be returned to service shortly. 

GE Healthcare representatives are contacting all known medical facilities that have a GE system to arrange for an inspection. For questions about this recall, contact your GE Healthcare service representative at (800) 437-1171.??

Read the July 3 recall letter here.

Related Content

ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Overlay Init